TWI659968B - 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 - Google Patents
針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 Download PDFInfo
- Publication number
- TWI659968B TWI659968B TW103108584A TW103108584A TWI659968B TW I659968 B TWI659968 B TW I659968B TW 103108584 A TW103108584 A TW 103108584A TW 103108584 A TW103108584 A TW 103108584A TW I659968 B TWI659968 B TW I659968B
- Authority
- TW
- Taiwan
- Prior art keywords
- rsv
- antibody
- antigen
- seq
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
- G01N2333/135—Respiratory syncytial virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782215P | 2013-03-14 | 2013-03-14 | |
| US61/782,215 | 2013-03-14 | ||
| US201361911093P | 2013-12-03 | 2013-12-03 | |
| US61/911,093 | 2013-12-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201444866A TW201444866A (zh) | 2014-12-01 |
| TWI659968B true TWI659968B (zh) | 2019-05-21 |
Family
ID=50391532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103108584A TWI659968B (zh) | 2013-03-14 | 2014-03-12 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9447173B2 (https=) |
| EP (1) | EP2968534B1 (https=) |
| JP (1) | JP6537492B2 (https=) |
| KR (1) | KR102211907B1 (https=) |
| CN (1) | CN105050622B (https=) |
| AU (1) | AU2014244411B2 (https=) |
| BR (1) | BR112015019066A2 (https=) |
| CA (1) | CA2904995A1 (https=) |
| CL (1) | CL2015002570A1 (https=) |
| EA (1) | EA034767B1 (https=) |
| IL (1) | IL240067A0 (https=) |
| MX (1) | MX360253B (https=) |
| MY (1) | MY174772A (https=) |
| PH (1) | PH12015501558B1 (https=) |
| SG (2) | SG11201505338RA (https=) |
| TW (1) | TWI659968B (https=) |
| UY (1) | UY35416A (https=) |
| WO (1) | WO2014159822A2 (https=) |
| ZA (1) | ZA201504952B (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| PL3204095T3 (pl) | 2014-10-10 | 2019-10-31 | Ablynx Nv | Urządzenie do inhalacji do stosowania w terapii aerozolowej chorób układu oddechowego |
| RU2017115670A (ru) | 2014-10-10 | 2018-11-15 | Аблинкс Н.В. | Лечение инфекции рсв |
| US9340604B1 (en) * | 2014-10-29 | 2016-05-17 | Aridis Pharmaceuticals, Inc. | Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV) |
| US20180171125A1 (en) | 2015-06-25 | 2018-06-21 | Sabic Global Technologies B.V. | Polymer composition comprising linear low-density polyethylene |
| EP3317290A4 (en) * | 2015-07-02 | 2019-04-10 | Spring Bank Pharmaceuticals, Inc. | COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
| CN106496324B (zh) * | 2015-11-30 | 2020-01-14 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| JP2020503843A (ja) | 2016-10-21 | 2020-02-06 | アディマブ， エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
| WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| CN110035771B (zh) * | 2016-10-21 | 2024-03-08 | 阿迪马布有限责任公司 | 抗呼吸道合胞病毒抗体及其产生和使用方法 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| KR102659791B1 (ko) | 2017-07-06 | 2024-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| WO2019075433A1 (en) * | 2017-10-13 | 2019-04-18 | Adimab, Llc | ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUS AND METHODS FOR THEIR GENERATION AND USE |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| CN111936513A (zh) * | 2018-01-31 | 2020-11-13 | 威斯塔解剖学和生物学研究所 | 用于抗呼吸道合胞病毒的核酸抗体构筑体 |
| CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3089655C (en) | 2018-03-19 | 2026-01-20 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| AU2019333047A1 (en) | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| US20210347885A1 (en) * | 2018-09-21 | 2021-11-11 | The University Of North Carolina At Chapel Hill | Synthetic binding agents for limiting permeation through mucus |
| WO2020124846A1 (zh) * | 2018-12-18 | 2020-06-25 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
| ES2942024T3 (es) | 2019-01-16 | 2023-05-29 | Regeneron Pharma | Métodos para caracterizar enlaces disulfuro |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| EP4653865A3 (en) | 2019-09-24 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| WO2021108548A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| MX2022008973A (es) | 2020-01-21 | 2022-08-11 | Regeneron Pharma | Metodos de desglicosilacion para electroforesis de proteinas glicosiladas. |
| AU2021332355A1 (en) | 2020-08-31 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| JP2024500409A (ja) | 2020-12-17 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質封入マイクロゲルの作製 |
| KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
| IL305156A (en) | 2021-03-03 | 2023-10-01 | Regeneron Pharma | Systems and methods for quantifying and modifying protein viscosity |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| EP4348234B1 (en) | 2021-06-01 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| JP2024531800A (ja) | 2021-09-20 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体の不均一性を制御する方法 |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| IL315548A (en) | 2022-03-18 | 2024-11-01 | Regeneron Pharma | Methods and systems for analyzing polypeptide variants |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| EP4704808A1 (en) | 2023-05-01 | 2026-03-11 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| TW202528736A (zh) | 2023-09-08 | 2025-07-16 | 美商再生元醫藥公司 | 用於評估層析管柱完整性的方法及系統 |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| CN121925272A (zh) | 2023-09-29 | 2026-04-24 | 瑞泽恩制药公司 | 利用受控成核进行冻干 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025104604A1 (en) | 2023-11-14 | 2025-05-22 | Janssen Pharmaceuticals, Inc. | Anti-respiratory syncytial virus antibodies and uses thereof |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194126A1 (en) * | 2024-03-15 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| DE69332643T2 (de) | 1992-09-16 | 2003-11-27 | The Scripps Research Institute, La Jolla | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| DE69609188T2 (de) | 1995-09-18 | 2000-12-21 | Intracel Corp., Issaquah | Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus |
| AR030019A1 (es) * | 1999-05-18 | 2003-08-13 | Smithkline Beecham Corp | Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| CA2398466A1 (en) | 2000-01-27 | 2001-08-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
| EP2341075A1 (en) | 2000-03-01 | 2011-07-06 | MedImmune, LLC | Antibodies binding to the f protein of a respiratory syncytial virus (rsv) |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US20060083741A1 (en) | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| JP2009528828A (ja) * | 2006-03-06 | 2009-08-13 | シムフォゲン・アクティーゼルスカブ | 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| BRPI0819210A2 (pt) | 2007-10-25 | 2015-06-23 | Trellis Bioscience Inc | Anticorpos de proteína g anti-rsv |
| US8852608B2 (en) * | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| PL2464664T3 (pl) | 2009-08-13 | 2016-02-29 | Crucell Holland Bv | Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania |
| US20110097358A1 (en) | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| CN102850454B (zh) * | 2011-09-27 | 2014-06-25 | 上海博沃生物科技有限公司 | 抗呼吸道合胞病毒的人单克隆抗体 |
| NZ630920A (en) | 2012-03-20 | 2017-01-27 | Humabs Biomed Sa | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
| LT2950886T (lt) | 2013-02-01 | 2020-07-10 | Medimmune, Llc | Respiracinio sincitinio viruso f baltymo epitopai |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| US10047145B2 (en) | 2013-07-24 | 2018-08-14 | Humabs Biomed Sa | Antibodies that potently neutralize RSV and uses thereof |
-
2014
- 2014-03-12 TW TW103108584A patent/TWI659968B/zh not_active IP Right Cessation
- 2014-03-13 MX MX2015009416A patent/MX360253B/es active IP Right Grant
- 2014-03-13 US US14/207,797 patent/US9447173B2/en active Active
- 2014-03-13 UY UY0001035416A patent/UY35416A/es not_active Application Discontinuation
- 2014-03-13 BR BR112015019066A patent/BR112015019066A2/pt not_active IP Right Cessation
- 2014-03-13 CA CA2904995A patent/CA2904995A1/en not_active Abandoned
- 2014-03-13 JP JP2016501801A patent/JP6537492B2/ja active Active
- 2014-03-13 CN CN201480014354.XA patent/CN105050622B/zh not_active Expired - Fee Related
- 2014-03-13 EP EP14714125.3A patent/EP2968534B1/en active Active
- 2014-03-13 SG SG11201505338RA patent/SG11201505338RA/en unknown
- 2014-03-13 SG SG10201610336QA patent/SG10201610336QA/en unknown
- 2014-03-13 WO PCT/US2014/025259 patent/WO2014159822A2/en not_active Ceased
- 2014-03-13 MY MYPI2015702227A patent/MY174772A/en unknown
- 2014-03-13 AU AU2014244411A patent/AU2014244411B2/en not_active Ceased
- 2014-03-13 KR KR1020157021198A patent/KR102211907B1/ko not_active Expired - Fee Related
- 2014-03-13 EA EA201591771A patent/EA034767B1/ru unknown
-
2015
- 2015-07-09 ZA ZA2015/04952A patent/ZA201504952B/en unknown
- 2015-07-13 PH PH12015501558A patent/PH12015501558B1/en unknown
- 2015-07-21 IL IL240067A patent/IL240067A0/en unknown
- 2015-09-10 CL CL2015002570A patent/CL2015002570A1/es unknown
-
2016
- 2016-08-05 US US15/229,567 patent/US10125188B2/en active Active
-
2018
- 2018-10-15 US US16/160,374 patent/US20190031741A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Wu H et al, "Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.", J Mol Biol. 2007 May 4;368(3):652-65. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI659968B (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| US12116401B2 (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| US20250388653A1 (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| US12215141B2 (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| EP3695003A1 (en) | Anti-respiratory syncytial virus antibodies, methods of their generation and use | |
| NZ710829B2 (en) | Human antibodies to respiratory syncytial virus f protein and methods of use thereof | |
| HK1220372B (en) | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |